COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
- PMID: 33437743
- PMCID: PMC7787016
- DOI: 10.34171/mjiri.34.147
COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities
Abstract
The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.
Keywords: ACE2 inhibitors; Associated comorbidities; COVID-19; Treatment; Type 2 diabetes.
© 2020 Iran University of Medical Sciences.
Conflict of interest statement
Conflicts of Interest: None declared
Similar articles
-
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26. High Blood Press Cardiovasc Prev. 2021. PMID: 33635533 Free PMC article. Review.
-
The Impact of Angiotensin-Converting Enzyme 2 (ACE2) Expression Levels in Patients with Comorbidities on COVID-19 Severity: A Comprehensive Review.Microorganisms. 2021 Aug 9;9(8):1692. doi: 10.3390/microorganisms9081692. Microorganisms. 2021. PMID: 34442770 Free PMC article. Review.
-
Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.Eur J Pharmacol. 2021 Apr 5;896:173899. doi: 10.1016/j.ejphar.2021.173899. Epub 2021 Jan 27. Eur J Pharmacol. 2021. PMID: 33508281 Free PMC article. Review.
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.Diabetes Metab Syndr. 2020 Jul-Aug;14(4):349-350. doi: 10.1016/j.dsx.2020.04.019. Epub 2020 Apr 15. Diabetes Metab Syndr. 2020. PMID: 32311651 Free PMC article.
-
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin system.Cardiovasc Diabetol. 2021 Apr 27;20(1):90. doi: 10.1186/s12933-021-01275-w. Cardiovasc Diabetol. 2021. PMID: 33906662 Free PMC article.
Cited by
-
The Association between Presence of Comorbidities and COVID-19 Severity: A Systematic Review and Meta-Analysis.Cerebrovasc Dis. 2021;50(2):132-140. doi: 10.1159/000513288. Epub 2021 Feb 2. Cerebrovasc Dis. 2021. PMID: 33530081 Free PMC article.
-
Prospective Medicinal Plants and Their Phytochemicals Shielding Autoimmune and Cancer Patients Against the SARS-CoV-2 Pandemic: A Special Focus on Matcha.Front Oncol. 2022 May 18;12:837408. doi: 10.3389/fonc.2022.837408. eCollection 2022. Front Oncol. 2022. PMID: 35664773 Free PMC article. Review.
-
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26. High Blood Press Cardiovasc Prev. 2021. PMID: 33635533 Free PMC article. Review.
-
Rational use of drugs to alleviate adverse outcomes caused by COVID-19 quarantine in women with intrahepatic cholestasis of pregnancy.Front Med (Lausanne). 2023 Aug 7;10:1122873. doi: 10.3389/fmed.2023.1122873. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37608824 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources